Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16)

Regulatory Peptides

Volumn 135, Issue 1-2, 2006, Pages 45-53

  Irwin, Nigel ^a   Green, Brian D ^a   Parker, Jeremy C ^a   Gault, Victor A ^a   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Bioactivity; C terminal truncation; Glucose dependent insulinotropic polypeptide (GIP); Obese diabetic ob ob mice

Indexed keywords

ANTIDIABETIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE [1-16]; GASTRIC INHIBITORY POLYPEPTIDE [1-16] 3 PROLINE; GASTRIC INHIBITORY POLYPEPTIDE [1-42]; GLUCOSE; HEMOGLOBIN A1C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; BODY WEIGHT; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEEDING; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; METABOLISM; MOLECULAR WEIGHT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN MODIFICATION; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; HOMEOSTASIS; INSULIN; MICE; MICE, OBESE; MOLECULAR WEIGHT; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 33744544382     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.03.006     Document Type: Article

References (26)

1. Gault V.A., O'Harte F.P., and Flatt P.R. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?. Neuropeptides 37 5 (2003) 253-263
2. Wang Y., Montrose-Rafizadeh C., Adams L., Raygada M., Nadiv O., and Egan J.M. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol Cell Endocrinol 116 1 (1996) 81-87
3. Ehses J.A., Casilla V.R., Doty T., Pospisilik J.A., Winter K.D., Demuth H.U., Pederson R.A., and McIntosh C.H. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144 10 (2003) 4433-4445
4. Trumper A., Trumper K., and Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174 2 (2002) 233-246
5. O'Harte F.P.M., Gray A.M., and Flatt P.R. Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J Endocrinol 156 2 (1998) 237-243
6. Andersen D.K., Putnam W.S., Hanks J.B., Wise J.E., Lebovitz H.E., and Jones R.S. Gastric inhibitory polypeptide (GIP) suppression of hepatic glucose production. Regul Pept 1 S1 (1980) S4
7. Oben J., Morgan L.M., Fletcher J., and Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36)amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 130 2 (1991) 267-272
8. Knapper J.M., Puddicombe S.M., Morgan L.M., and Fletcher J.M. Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat tissue. J Nutr 125 2 (1995) 183-188
9. Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 109 S2 (2001) S288-S303
10. Hinke S.A., Manhart S., Pamir N., Demuth H., W Gelling R., Pederson R.A., and McIntosh C.H. Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim Biophys Acta 1547 1 (2001) 143-155
11. Gault V.A., Harriott P., Flatt P.R., and O'Harte F.P.M. Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide. Biosci Rep 22 5-6 (2002) 523-528
12. Morrow G.W., Kieffer T.J., McIntosh C.H., MacGillivray R.T., Brown J.C., St Pierre S., and Pederson R.A. The insulinotropic region of gastric inhibitory polypeptide; fragment analysis suggests the bioactive site lies between residues 19 and 30. Can J Physiol Pharmacol 74 1 (1996) 65-72
13. Manhart S., Hinke S.A., McIntosh C.H., Pederson R.A., and Demuth H.U. Structure-function analysis of a series of novel GIP analogues containing different helical length linkers. Biochemistry 42 10 (2003) 3081-3088
14. Hinke S.A., Manhart S., Speck M., Pederson R.A., Demuth H.U., and McIntosh C.H. In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide. Life Sci 75 15 (2004) 1857-1870
15. Gault V.A., Parker J.C., Harriott P., Flatt P.R., and O'Harte F.P.M. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 175 2 (2002) 525-533
16. Gault V.A., O'Harte F.P.M., Harriott P., and Flatt P.R. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290 5 (2002) 1420-1426
17. Alana I., Hewage C.M., Malthouse J.P., Parker J.C., Gault V.A., and O'Harte F.P.M. NMR structure of the glucose-dependent insulinotropic polypeptide fragment, GIP(1-30)amide. Biochem Biophys Res Commun 325 1 (2004) 281-286
18. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54 8 (2005) 2436-2446
19. Flatt P.R., and Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20 5 (1981) 573-577
20. Stevens J.F. Determination of glucose by an automatic analyser. Clin Chem Acta 32 2 (1971) 199-201
21. Burington R.S. Handbook of mathematical tables and formulae (1973), McGraw-Hill, New York
22. 2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo. J Biol Chem 279 6 (2003) 3998-4006
23. Lindsay J.R., Au S.T.B., Kelly C.M.N., O'Harte F.P.M., and Flatt P.R. A novel amino-terminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with a prolonged insulinotropic activity in type 2 diabetes mellitus. Diabetes S5 (2002) 1394
24. O'Harte F.P., Gault V.A., Parker J.C., Harriott P., Mooney M.H., Bailey C.J., and Flatt P.R. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45 9 (2002) 1281-1291
25. 3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic ob/ob mice: evidence that GIP is the major physiological incretin. Diabetologia 46 2 (2003) 222-230
26. Woods S.C., West D.B., Stein L.J., McKay L.D., Lotter E.C., Porte S.G., Kenney N.J., and Porte Jr. D. Peptides and the control of meal size. Diabetologia 20 S1 (1981) 305-313